Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA-Reference-Cited by-同舟云学术

Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA

Published:2024-02-01 Issue: Volume: Page:
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Lin Shih-Wen^ORCID,Shapouri Sheila,Parisé Hélène,Bercaw Eric,Wu Mei,Kim Eunice,Matasar Matthew

Funder

F. Hoffmann-La Roche Ltd

Genentech, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-024-01358-y.pdf

Reference67 articles.

1. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848–57. https://doi.org/10.1016/s0140-6736(12)60605-9.

2. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298–310. https://doi.org/10.1016/s0140-6736(16)32407-2.

3. National Cancer Institute. Adult non-Hodgkin lymphoma treatment (PDQ®), Health Professional Version. 2022. Available from: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq. [Accessed 6 Dec 2022].

4. Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316–27. https://doi.org/10.1002/ajh.25696.

5. US Food and Drug Administration. FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns. 2022. Available from: https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-withdrew-its-approval-cancer-medicine-ukoniq-umbralisib-due-safety-concerns. [Accessed 1 Jun 2022].